Cargando…
Addendum: Successful administration of sequential TVEC and pembrolizumab followed by Temozolomide in immunotherapy refractory intracranial metastatic melanoma with acquired B2M mutation
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Impact Journals LLC
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9924826/ https://www.ncbi.nlm.nih.gov/pubmed/36780317 http://dx.doi.org/10.18632/oncotarget.28365 |
| _version_ | 1784887931216855040 |
|---|---|
| author | Khaddour, Karam Dowling, Joshua Huang, Jiayi Council, Martha Chen, David Cornelius, Lynn Johanns, Tanner Dahiya, Sonika Ansstas, George |
| author_facet | Khaddour, Karam Dowling, Joshua Huang, Jiayi Council, Martha Chen, David Cornelius, Lynn Johanns, Tanner Dahiya, Sonika Ansstas, George |
| author_sort | Khaddour, Karam |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9924826 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Impact Journals LLC |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-99248262023-02-14 Addendum: Successful administration of sequential TVEC and pembrolizumab followed by Temozolomide in immunotherapy refractory intracranial metastatic melanoma with acquired B2M mutation Khaddour, Karam Dowling, Joshua Huang, Jiayi Council, Martha Chen, David Cornelius, Lynn Johanns, Tanner Dahiya, Sonika Ansstas, George Oncotarget Addendum Impact Journals LLC 2023-02-11 /pmc/articles/PMC9924826/ /pubmed/36780317 http://dx.doi.org/10.18632/oncotarget.28365 Text en Copyright: © 2023 Khaddour et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
| spellingShingle | Addendum Khaddour, Karam Dowling, Joshua Huang, Jiayi Council, Martha Chen, David Cornelius, Lynn Johanns, Tanner Dahiya, Sonika Ansstas, George Addendum: Successful administration of sequential TVEC and pembrolizumab followed by Temozolomide in immunotherapy refractory intracranial metastatic melanoma with acquired B2M mutation |
| title | Addendum: Successful administration of sequential TVEC and pembrolizumab followed by Temozolomide in immunotherapy refractory intracranial metastatic melanoma with acquired B2M mutation |
| title_full | Addendum: Successful administration of sequential TVEC and pembrolizumab followed by Temozolomide in immunotherapy refractory intracranial metastatic melanoma with acquired B2M mutation |
| title_fullStr | Addendum: Successful administration of sequential TVEC and pembrolizumab followed by Temozolomide in immunotherapy refractory intracranial metastatic melanoma with acquired B2M mutation |
| title_full_unstemmed | Addendum: Successful administration of sequential TVEC and pembrolizumab followed by Temozolomide in immunotherapy refractory intracranial metastatic melanoma with acquired B2M mutation |
| title_short | Addendum: Successful administration of sequential TVEC and pembrolizumab followed by Temozolomide in immunotherapy refractory intracranial metastatic melanoma with acquired B2M mutation |
| title_sort | addendum: successful administration of sequential tvec and pembrolizumab followed by temozolomide in immunotherapy refractory intracranial metastatic melanoma with acquired b2m mutation |
| topic | Addendum |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9924826/ https://www.ncbi.nlm.nih.gov/pubmed/36780317 http://dx.doi.org/10.18632/oncotarget.28365 |
| work_keys_str_mv | AT khaddourkaram addendumsuccessfuladministrationofsequentialtvecandpembrolizumabfollowedbytemozolomideinimmunotherapyrefractoryintracranialmetastaticmelanomawithacquiredb2mmutation AT dowlingjoshua addendumsuccessfuladministrationofsequentialtvecandpembrolizumabfollowedbytemozolomideinimmunotherapyrefractoryintracranialmetastaticmelanomawithacquiredb2mmutation AT huangjiayi addendumsuccessfuladministrationofsequentialtvecandpembrolizumabfollowedbytemozolomideinimmunotherapyrefractoryintracranialmetastaticmelanomawithacquiredb2mmutation AT councilmartha addendumsuccessfuladministrationofsequentialtvecandpembrolizumabfollowedbytemozolomideinimmunotherapyrefractoryintracranialmetastaticmelanomawithacquiredb2mmutation AT chendavid addendumsuccessfuladministrationofsequentialtvecandpembrolizumabfollowedbytemozolomideinimmunotherapyrefractoryintracranialmetastaticmelanomawithacquiredb2mmutation AT corneliuslynn addendumsuccessfuladministrationofsequentialtvecandpembrolizumabfollowedbytemozolomideinimmunotherapyrefractoryintracranialmetastaticmelanomawithacquiredb2mmutation AT johannstanner addendumsuccessfuladministrationofsequentialtvecandpembrolizumabfollowedbytemozolomideinimmunotherapyrefractoryintracranialmetastaticmelanomawithacquiredb2mmutation AT dahiyasonika addendumsuccessfuladministrationofsequentialtvecandpembrolizumabfollowedbytemozolomideinimmunotherapyrefractoryintracranialmetastaticmelanomawithacquiredb2mmutation AT ansstasgeorge addendumsuccessfuladministrationofsequentialtvecandpembrolizumabfollowedbytemozolomideinimmunotherapyrefractoryintracranialmetastaticmelanomawithacquiredb2mmutation |